Patient Leaflet Updated 18-Jul-2024 | AstraZeneca UK Limited
Truqap 160 mg and 200 mg film-coated tablets
Truqap® 160 mg film-coated tablets
Truqap® 200 mg film-coated tablets
capivasertib
▼This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.
1. What Truqap is and what it is used for
2. What you need to know before you take Truqap
3. How to take Truqap
4. Possible side effects
5. How to store Truqap
6. Contents of the pack and other information
Truqap is a medicine used to treat cancer. It contains the active substance capivasertib. Capivasertib belongs to a group of medicines called AKT inhibitors.
Truqap is available in 160 mg and 200 mg tablets.
Truqap in combination with fulvestrant is used to treat adult patients who have hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer that is advanced or that has spread to other parts of the body with one or more abnormal “PIK3CA”, “AKT1”, or “PTEN” gene and whose cancer is not responding to other anti-hormonal based therapies.
Your healthcare provider will test your cancer to see if it has at least one abnormal “PIK3CA”, “AKT1”, or “PTEN” gene to make sure that Truqap is right for you.
Truqap works by blocking the effects of proteins called AKT Kinases. These proteins help cancer cells to grow and multiply. By blocking their action, Truqap can reduce growth and spread of the cancer and help to destroy cancer cells.
If you have any questions about how Truqap works or why this medicine has been prescribed for you, ask your doctor.
Follow your doctor’s instructions carefully, as they may differ from the general information in this leaflet. Check with your doctor if you are not sure.
You are allergic to capivasertib or any of the other ingredients of this medicine (listed in section 6).
If you think you may be allergic, ask your doctor for advice.
Before you take Truqap, tell your healthcare provider if:
You should read the Package Leaflet of fulvestrant for important information on warnings and precautions.
Your doctor may need to treat these symptoms, temporarily pause your treatment, reduce your dose, or permanently stop your treatment with Truqap.
Do not give this medicine to children or adolescents under 18 years of age.
Tell your doctor or pharmacist or nurse if you are taking, have recently taken or might take any other medicines. Some medicines may increase the risk of side effects of Truqap. See examples below:
Some medicines may reduce the effectiveness of Truqap, for example carbamazepine, phenytoin, St. John’s wort (an herbal medicine), and rifampicin.
Ask your doctor or pharmacist or nurse if you are not sure whether your medicine is one of the medicines listed above. The medicines listed here may not be the only ones that could interact with Truqap.
Do not take Truqap if you are pregnant.
If you are a woman who could become pregnant, your doctor will ask you to provide a negative pregnancy test prior to starting treatment and advise you to perform a pregnancy test during your treatment.
If you are a woman, you should avoid becoming pregnant while taking Truqap. Discuss contraception with your doctor if there is any possibility that you may become pregnant. If you are a woman who could become pregnant, you should use an effective method of birth control during treatment with Truqap and for 4 weeks after the last dose. If you do become pregnant during treatment, tell your doctor immediately.
If you are a man, you must use a condom when having sexual intercourse with a female partner who is or could become pregnant while you are taking Truqap and for 16 weeks after the last dose. Your female partner must also use an effective method of contraception. You must tell your doctor if your female partner becomes pregnant.
Before taking Truqap, tell your doctor if you are breast-feeding. For the safety of your baby, you should not breast-feed during the treatment with Truqap.
Truqap may affect your ability to drive or use machines. If you feel tired while taking Truqap, take special care when driving or using tools or machines.
This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium free’.
Always take this medicine exactly as your doctor or pharmacist or nurse has told you. Check with your doctor or pharmacist or nurse if you are not sure.
The usual starting dose of Truqap is 400 mg (two 200 mg tablets) taken:
Truqap weekly dosing schedule
Morning (sun image) – Day 1, 2, 3 & 4 – 2 x 200 mg, no dosing on days 5, 6 & 7
Evening (moon image) - Day 1, 2, 3 & 4 – 2 x 200 mg, no dosing on days 5, 6 & 7
Swallow Truqap tablets whole with water, do not chew, crush or split them before swallowing. Do not swallow any tablet that is broken, cracked or otherwise damaged as you may not be taking the full dose.
If you vomit, do not take an additional dose. Take the next dose of Truqap at your usual time.
Avoid high doses of grapefruit and grapefruit juice while you are taking Truqap as it may increase the side effects of Truqap.
Depending on how your body responds to the treatment with Truqap, your doctor may want to adjust your Truqap dose. It is very important to follow your doctor’s instructions. If you have certain side effects, your doctor may ask you to change to a lower dose, to pause treatment for a time, or to stop treatment.
The number of tablets to take depends on the dose prescribed as below:
When you take this medicine, you will also receive another medicine called fulvestrant. Your doctor will determine the dose and the schedule for fulvestrant.
During your treatment with Truqap, for women who have not reached menopause, your doctor will prescribe a medicine called a luteinising hormone-releasing hormone (LHRH) agonist. For men, your healthcare provider may prescribe a LHRH agonist to take with Truqap and fulvestrant.
Take Truqap for as long as your doctor tells you to.
This is a long-term treatment, possibly lasting for months or years. Your doctor will regularly monitor your condition to check that the treatment is having the desired effect. If you have questions about how long to take Truqap, talk to your doctor or pharmacist or nurse.
If you take too many tablets, or if someone else takes your medicine, contact a doctor or hospital for advice immediately. Show the Truqap packet. Medical treatment may be necessary.
If you miss a dose, you may still take it within 4 hours from the time you usually take it.
If it has been more than 4 hours after you usually take your dose, skip that dose. Take the next dose at your usual time. Refer to Table 1 for dosing schedule. Do not take two doses to make up for a missed dose.
Do not stop taking Truqap unless your doctor tells you to. If you have any further questions on the use of this medicine, ask your doctor or pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some side effects could be serious.
Immediately talk to your doctor if you experience the following during treatment with Truqap. Your doctor may need to treat these symptoms, temporarily pause your treatment, reduce your dose, or permanently stop your treatment with Truqap.
High blood sugar levels (hyperglycaemia, very common)
Skin reactions (very common)
Tell your doctor or pharmacist or nurse if you notice any of the following side effects:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after “EXP”. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not use this medicine if you notice any damage to the packaging or if the tablet is broken, cracked, or otherwise not intact.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substance of Truqap is capivasertib.
The other excipients are:
Truqap 160 mg film-coated tablets
Round, biconvex, beige film-coated tablets debossed with ‘CAV’ above ‘160’ on one side and plain on the reverse. Approximate diameter: 10 mm.
Truqap 200 mg film-coated tablets
Capsule shaped, biconvex, beige film-coated tablets debossed with ‘CAV 200’ on one side and plain on the reverse. Approximate size: 14.5 mm (length), 7.25 mm (width).
Truqap is supplied in a pack size of 64 tablets, comprising four Alu/Alu blisters of 16 tablets.
This leaflet was last revised in June 2024
© AstraZeneca 2024
Truqap is a registered trademark of the AstraZeneca group of companies.
ONC 23 0024c
Other sources of information
To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge:
0800 198 5000
Please be ready to give the following information:
Product name Marketing Authorisation number
Truqap 160 mg film-coated tablets PLGB 17901/0373
Truqap 200 mg film-coated tablets PLGB 17901/0374
This is a service provided by the Royal National Institute of the Blind.
2 Pancras Square, 8th Floor, London, N1C 4AG, UK
+44 (0)1582 838 000
www.myazmed.co.uk
+44 (0)1582 836 000
0800 783 0033
https://medicalinformation.astrazeneca.co.uk/